- Home
- RAC vs RIGL Comparison
RAC vs RIGL Comparison
Compare RAC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAC
- RIGL
- Stock Information
- Founded
- RAC 2024
- RIGL 1996
- Country
- RAC United States
- RIGL United States
- Employees
- RAC N/A
- RIGL N/A
- Industry
- RAC
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- RAC
- RIGL Health Care
- Exchange
- RAC Nasdaq
- RIGL Nasdaq
- Market Cap
- RAC 302.3M
- RIGL 335.5M
- IPO Year
- RAC 2025
- RIGL 2000
- Fundamental
- Price
- RAC $10.30
- RIGL $41.50
- Analyst Decision
- RAC
- RIGL Buy
- Analyst Count
- RAC 0
- RIGL 5
- Target Price
- RAC N/A
- RIGL $38.20
- AVG Volume (30 Days)
- RAC 115.0
- RIGL 845.0K
- Earning Date
- RAC 01-01-0001
- RIGL 08-05-2025
- Dividend Yield
- RAC N/A
- RIGL N/A
- EPS Growth
- RAC N/A
- RIGL N/A
- EPS
- RAC N/A
- RIGL 5.43
- Revenue
- RAC N/A
- RIGL $267,921,000.00
- Revenue This Year
- RAC N/A
- RIGL $14.41
- Revenue Next Year
- RAC N/A
- RIGL $15.97
- P/E Ratio
- RAC N/A
- RIGL $7.64
- Revenue Growth
- RAC N/A
- RIGL 105.62
- 52 Week Low
- RAC $10.00
- RIGL $12.00
- 52 Week High
- RAC $10.70
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- RAC N/A
- RIGL 86.20
- Support Level
- RAC N/A
- RIGL $38.43
- Resistance Level
- RAC N/A
- RIGL $41.25
- Average True Range (ATR)
- RAC 0.00
- RIGL 2.50
- MACD
- RAC 0.00
- RIGL 0.89
- Stochastic Oscillator
- RAC 0.00
- RIGL 89.85
About RAC Rithm Acquisition Corp. Class A Ordinary Shares
Rithm Acquisition Corp is a blank check company.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.